1. Reasons to Choose Taiwan UBI Asia in Partnership with UBI
Chang Yi Wang, PhD
Founder, UBI
Chairperson, UBI Asia

2. Core Technology UBI / UBI Asia Cytotoxic T Neutralization Lymphocyte
Functional
Antigenics
UBI / UBI Asia
Molecular
Design of
Functional
Antigens
Adjuvant &
Formulation
Technologies
UBITh ®
Technology
Synthetic
Peptide
Antigenic
Combinatorial
Library
Cytotoxic T
Lymphocyte
Neutralization
Antibodies
Antibody
Deimmunization
Immunodiagnostics
Therapeutic
Monoclonal
Antibodies
Vaccines and
Immunotherapeutics

3. Product Portfolios Vaccines & Immunotherapeutics Functional Antigenics
LHRH Vaccine
as Prostate Cancer
Therapeutic
HIV/AIDS Vaccine & Therapeutic
Allergy Therapeutic
Alzheimer Disease
SARS Vaccine
& Diagnostics
Canine Allergy
Therapeutic
FMDV Vaccine &
Diagnostics
LHRH Vaccine
for Boar Taint Removal &
Growth Promotion
as Pet Contraceptive
Functional
Antigenics
Animal Health Products
Human Health Products

4. Business partners and Product Development Sponsors of UBI
Division of AIDS, NIAID, NIH, USA [HIV Immunotherapeutics]
NIAID, NIH, USA [Allergy Immunotherapeutic]
NCI, NIH, USA [Prostate Cancer Immunotherapeutic]
Baxter, USA
BioMerieux (Lyon, France), formerly Organon Teknika of Akzo Nobel (Boxtel, Netherlands)
Merial (Lyon, France) (JV of Merck and Aventis, largest animal health company in the world)
The United Laboratories (Zhuhai, China)
China Animal Husbandry Industry Corp. (Beijing, China)

5. Synergy: Traditional Pharma / Innovative Bio
Peptide Pilot
Plant
Protein Drug
Pilot Plant
Biologics
Manufacture Plant
cGMP
Roche
GSK
BioPharmaceutics
Foundation in
Taiwan
Toll Manufacture
Pharmaceutics
Foundation in Taiwan
Compliance with FDA
International
BioPharmaceutics
Company
Specialty Injectables

6. Business Model rowth Survival Synergy cGMP Pharmaceutical Plants
Pharma / Bio
UBI / UBI Asia
rowth

7. Survival: Conservative Nurtures High Risk
UBI
技術轉移
UBI Asia
技術承接 &
產品創新研發
cGMP
Manufacture
Acquire Roche & GSK cGMP plants:
Chemical drugs, Biologics
1999
2002
Innovative
R & D
Peptide based:
Vaccine & diagnostics
Protein based:
Therapeutic monoclonal antibodies

8. From Genomics to Products Innovation Through Design
UBI
Asia
FMDV Vaccine: Ko-T Con ® 口蹄安
FMDV Diagnostics
From Genomics to Products
Innovation Through Design

9. Complete Replacement of Traditional Vaccines
The Vision:
Complete Replacement of Traditional Vaccines
within 5 Years !!

10. From Genomics to Products Innovation Through Design
UBI
Asia
UBITh® LHRH Immunotherapeutic
Boar Taint Removal Vaccine: Bota Con ® 寶特康
Pet Contraceptive Vaccine
Human Prostate Cancer Therapeutic
From Genomics to Products
Innovation Through Design

11. BotaCon ®寶特康:
An Immunotherapeutic to eliminate Boar Taint and promote pig growth and

12. Cattle

13. UBI
Asia
Therapeutic Monoclonal Antibodies

14. Monoclonal Antibody Engineering
Monoclonal Antibody Humanization (Murine Ab to Human Ab)
Hybridoma,
Cesar Milstein &
Georges Kohler
Chimeric mAb, Genentech Fc Fv
CDR grafting, PDL
1975
1994
1986
OKT3, 1986, 55 M USD
RePro, 1994, 447 M USD
Rituxan, 1997, 298 M USD
Deimmunization, Biovation
1998
Identification of
T cell and B cell
antigenic epitopes in
Variable regions

15. Well-Characterized Monoclonal Antibody (B4) directed against HIV receptor complex for treatment of HARRT resistant AIDS patients through entry inhibition

16. UBI Asia provides services to and collaborates with multiple commercial and research institutes
先導工廠
聯亞研發中心
產程發展 &
原料藥生產
UBI Asia R & D
聯亞生產中心
聯亞cGMP廠
西藥 &
生技藥品
劑型生產
配方研發
臨床試驗
產品登記

17. Vision: Designer Immunological Products UBI國際 臨床&事業 中心 UBI Asia 研發&生產
for the treatment, prevention, and diagnosis of
globally significant diseases
中國大陸 歐洲
東南亞
日本、韓國
UBI國際
臨床&事業 中心
美國、美洲 台 灣
UBI Asia
研發&生產

18. Synergy: UBI Asia / UBI MOEA UBI Asia NIH UBI R & D Center Basic
Research
Process
Development
Field &
Clinical Trials
UBI

19. Reasons to Choose Taiwan UBI Asia in Partnership with UBI
Taiwan government with policies to promote biotechnology
Taiwan has diligent, entrepreneurial and well-educated human resources
Operations can be cost effective when compared with the west
Easy access to fast breaking first hand business information
Access to huge China market due to similarity in language and cultural background
Training and testing ground for worldmarket due to its extensive connections to the western world

20. Join us, and
Welcome to Taiwan!